Latanoprost

  • # LGM Pharma is a Latanoprost CAS# 130209-82-4 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Latanoprost
  • CAS #: 130209-82-4
  • Mode of Action:

    Latanoprost is a prostaglandin F2a analogue. Specifically, Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Thought of as a plumbing problem for the eye, Glaucoma is essentially when the drainage system of the eye is clogged. This clogging increases ocular pressure (IOP) and damages the optic nerve, leading to the diagnosis of glaucoma. If patients experience a prolonged period of time with elevated eye pressure they may have significant vision loss as a repercussion.

  • Pharmacodynamics:

    Latanoprost is an isopropyl ester prodrug which is inactive but which becomes active after hydrolysis to the acid from. Latanoprost opthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes.

  • Metabolism:

    Primarily hepatic (none except hydrolysis in the eye). Latanoprost is an isopropyl ester prodrug. It is hydrolyzed by esterases in the cornea to latanoprost acid, which is biologically active. The portion of the latanoprost acid that reaches the systemic circulation is metabolized primarily by the liver to 1, 2-dinor and 1, 2, 3, 4-tetranor metabolites by fatty acid beta-oxidation.

  • Toxicity:

    Between 5 and 15 percent of patients administered Latanoprost for six months or longer report at least one adverse effect from this drug. Common side effects reported include redness, blurry vision, burning, itching and stinging in the eye. Latanoprost may cause a long term change in the color of eyes, eyelids and eyelashes. These changes occur gradually and may be permanent.  

  • IUPAC: propan-2-yl (5Z)-7-[(1R, 2R, 3R, 5S)-3, 5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
  • ATC: S01EE01
  • PubChem: 5311221
  • DrugBank: DB00654 (APRD01065)
  • Formula: C26-H40-O5
  • Molecular Mass: 432.597
  • Synonyms: Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate, Latanoprost, PhXA 41, PHXA41, UNII-6Z5B6HVF6O, XA 41, XA41, Xalatan
  • SMILES: CC(C)OC(=O)CCCC=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
  • AHFS Code: 53:32.0
  • InChl: GGXICVAJURFBLW-CEYXHVGTSA-N
  • Date Modified: 03-12-19
  • General Reference:

    Hara T: [Increased iris pigmentation after use of latanoprost in Japanese brown eyes]. Nippon Ganka Gakkai Zasshi. 2001 May;105(5):314-21. [PubMed:11406947]

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements
This website uses cookies. By using our site, you agree to our terms of service